Literature DB >> 29071006

The emerging role of CCN6 in breast cancer invasion.

Guadalupe Lorenzatti1, Wei Huang2, Celina G Kleer2.   

Abstract

The CCN family of matricellular proteins is essential for cell communication and mediation of epithelial stromal cross-talks with roles in development and cancer. In particular, loss of CCN6 messenger RNA expression has been recognized in highly aggressive breast cancers, especially in inflammatory breast cancer and breast cancers with axillary lymph node metastasis. Recent findings can better explain the relevance of CCN6's reduced expression on human invasive breast carcinomas. CCN6 has been shown to play a role in the process of epithelial to mesenchymal transition (EMT), which converts epithelial cells into migratory mesenchymal-like cells with invasive abilities. Although the mechanism by which CCN6 promotes EMT and invasion has not been fully elucidated, current data suggest that it involves the recruitment of the transcriptional regulators Snai1 and ZEB1 to the E-cadherin promoter.

Entities:  

Year:  2009        PMID: 29071006      PMCID: PMC5651983     

Source DB:  PubMed          Journal:  Cellscience        ISSN: 1742-8130


  57 in total

Review 1.  NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues.

Authors:  B Perbal
Journal:  Mol Pathol       Date:  2001-04

2.  Persistent E-cadherin expression in inflammatory breast cancer.

Authors:  C G Kleer; K L van Golen; T Braun; S D Merajver
Journal:  Mod Pathol       Date:  2001-05       Impact factor: 7.842

Review 3.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

4.  Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.

Authors:  Eva S Schernhammer; Jeff M Holly; Michael N Pollak; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-03       Impact factor: 4.254

5.  Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.

Authors:  Joan M Carboni; Adrian V Lee; Darryl L Hadsell; Bruce R Rowley; Francis Y Lee; David K Bol; Amy E Camuso; Marco Gottardis; Ann F Greer; Ching Ping Ho; Warren Hurlburt; Aixin Li; Mark Saulnier; Upender Velaparthi; Cindy Wang; Mei-Li Wen; Richard A Westhouse; Mark Wittman; Kurt Zimmermann; Brent A Rupnow; Tai W Wong
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

6.  Detection of frequent allelic loss of 6q23-q25.2 in microdissected human breast cancer tissues.

Authors:  H Fujii; W Zhou; E Gabrielson
Journal:  Genes Chromosomes Cancer       Date:  1996-05       Impact factor: 5.006

7.  DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells.

Authors:  Andreas Eger; Kirsten Aigner; Stefan Sonderegger; Brigitta Dampier; Susanne Oehler; Martin Schreiber; Geert Berx; Amparo Cano; Hartmut Beug; Roland Foisner
Journal:  Oncogene       Date:  2005-03-31       Impact factor: 9.867

8.  Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas.

Authors:  S A Chappell; T Walsh; R A Walker; J A Shaw
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer.

Authors:  Celina G Kleer; Yanhong Zhang; Quintin Pan; Sofia D Merajver
Journal:  Neoplasia       Date:  2004 Mar-Apr       Impact factor: 5.715

10.  The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity.

Authors:  K Aigner; B Dampier; L Descovich; M Mikula; A Sultan; M Schreiber; W Mikulits; T Brabletz; D Strand; P Obrist; W Sommergruber; N Schweifer; A Wernitznig; H Beug; R Foisner; A Eger
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.